WuXi Biologics is operating and building multiple state-of-the-art world-class cGMP Drug Substance (DS) and Drug Product (DP) facilities across four countries while growing globally over the next few years. We provide high-quality DS and DP where and when you need it. Let's Get Started. https://lnkd.in/eVbsdb-v #biopharmaceuticals #biotechnology #bioprocessing #biomanufacturing #biologics
WuXi Biologics/药明生物
制药业
Wuxi,Jiangsu 94,651 位关注者
A true global single-source drug development technology platform from concept to commercialization.
关于我们
WuXi Biologics provides a comprehensive, integrated and highly customizable range of services for the discovery, development and manufacturing of biologics. We are the only open-access biologics technology platform in the world offering end-to-end solutions to empower anyone to discover, develop and manufacture biologics from concept to commercial manufacturing. We provide the world with the ONE true single-source approach that saves our clients critical time and money.
- 网站
-
https://www.wuxibiologics.com/
WuXi Biologics/药明生物的外部链接
- 所属行业
- 制药业
- 规模
- 超过 10,001 人
- 总部
- Wuxi,Jiangsu
- 类型
- 上市公司
- 创立
- 2010
- 领域
- Biologics conjugation、Bioprocess CMC、Biosafety、Biologics GMP Manufacturing、Biologics discovery service、Cell Line Development、Formulation Development、Analytical Characterization、Cell Culture and Purification Process Development、Monoclonal Antibodies (mAbs)、vaccine development、vaccine manufacturing、antibody discovery、antibody manufacturing、protein production、analytical services、biotherapeutics、biopharmaceuticals和continuous manufacturing
地点
WuXi Biologics/药明生物员工
动态
-
Exciting News! WuXi Biologics just launched the WuXiaADCC PLUS™ platform, a novel development in afucosylated antibody production. We've created a host cell line that enhances ADCC effects, improving therapeutic efficacy, while simplifies the afucosylation process, eliminating the need for laborious treatments. Based on the WuXia™ CHO-K1 cell line, it maintains robust growth and metabolism, boasting an impressive average mAb clone titer of 6 g/L. This breakthrough ensures stable expression over long-term passages, facilitating scalable clinical and commercial manufacturing. Ready to elevate your cell line development? Explore the potential with WuXiaADCC PLUS™: https://lnkd.in/efexPBhp #Biotech #Innovation #WuXiBiologics #ADCC #AntibodyProduction#cell line development
-
-
WuXi Biologics is pleased to announce solid interim financial results for 2024, which shows how our CRDMO business model continues to sustain long-term growth. MNC’s acquisition of a client’s molecule positions a potential best-in-class CD3 asset that uses three of our technology platforms. Other highlights include: ⭐ 1% YoY revenue increase ⭐ 7.7% YoY non-COVID revenue growth ⭐ 742 total integrated projects with 61 new projects added ⭐ 13 successful product inspections by EMA and 2 by FDA For more highlights, please visit: https://lnkd.in/eA_4tZtk
-
Click to learn more about our high-quality mAbs production platform!
Case Study Spotlight: In this case study, we demonstrated our 777 platform’s ability to produce vanilla antibodies with exceptional purity, as confirmed by SEC-HPLC and Caliper-SDS. Our 777 service produces high-quality mAbs with low endotoxin (<0.5 EU/mg) and low aggregates (>95% monomer) in just 3 weeks at a scale of 1-100 mg, suitable for in vitro and in vivo studies. Learn More: ▶️https://shorturl.at/sPORY #casestudy #antibodyproduction #antibodydiscovery #monoclonalantibodies
-
-
🌟 Welcome to our August Newsletter on LinkedIn! 🌟 If you're developing protein-, viral-, or nucleic acid-based therapeutics, you know that optimizing formulation stability and efficacy is critical. At WuXi Biologics, we tackle these challenges head-on with our cutting-edge drug product (DP) development services. From liquid and frozen to lyophilized formulations, and delivery systems like liquid nanoparticles (LNPs), we've got you covered. Ready to stay ahead in the world of biopharma? Subscribe to "The Next Biologic" – where innovation meets inspiration! #biologics #drugdiscovery #drugdevelopment #biomanufacturing #bioprocessing #biopharmaceutical #drugproduct
-
WuXi Biologics published a research paper “Drug deconjugation-assisted peptide mapping by LC–MS/MS to identify conjugation sites and quantify site occupancy for antibody-drug conjugates” in Journal of Pharmaceutical and Biomedical Analysis. The paper has introduced an effective and straightforward tool for conjugation site analysis while simultaneously monitoring multiple quality attributes for ADCs. #ADC #CRDMO #biotech Click to read more: https://lnkd.in/ew-ru8z4
-
We understand that the journey from lab to patient is a complex one. That's why we've crafted a suite of Clinical In-Use (CIU) services designed to streamline the ADC drug product development process and ensure your product's success in the real world. Our CIU studies meticulously evaluate the stability and compatibility of your biological product across all intended administration routes. Learn more: https://lnkd.in/ggxuX863 #conjugate #conjugates #bioconjugation #bioconjugate #bioconjugates #adc #adcs #antibodydrugconjugate #antibodydrugconjugates #cmc #cdmo #crdmo #biomanufacturing #bioprocessing
-
-
Let's connect during BioProcess International / Biotech Week Boston (September 23-26) at booth #725. Our team will be available to discuss your R&D and drug manufacturing goals live in Boston. Contact us and we'll set up a convenient time to discuss your outsourcing or partnering needs. Request a meeting: https://lnkd.in/gvNFGynY #bioprocessing #biomanufacturing #drugdevelopment #drugmanufacturing
-
-
Service Spotlight: WuXi Biologics offers extensive lead assessment and optimization services for antibody therapeutics and other biologics. Our team of experts work with you to establish the best path in optimizing your molecule to its target and for its intended purpose. Let's get started. https://lnkd.in/ejJwMXNk #antibodydiscovery #leadoptimization #humanization #biologics #biotherapeutics #biopharma #drugdevelopment #drugdiscovery #biologics
-
-
Combination products (e.g., auto-injectors) offer numerous advantages in drug delivery, including enhanced treatment compliance and safety, more accurate dosing, and greater ease-of-use and flexibility for self-administration. Our Drug-Device Combination Center of Excellence specializes in combination product development, filling, and final assembly, providing a diverse selection of delivery systems that include needlestick injury protection features and auto-injector formats. https://lnkd.in/eUQJugYB https://lnkd.in/eUQJugYB
-